Amylyx Pharmaceuticals, Inc. 4

Camille L. Bedrosian, CMO of Amylyx Pharmaceuticals (AMLX), sold 10,028 shares of common stock on September 10, 2026 in tax-withholding transactions related to PSU vesting.

On September 10, 2026, Camille L. Bedrosian, Chief Medical Officer of Amylyx Pharmaceuticals, Inc., sold an aggregate 10,028 shares of Amylyx common stock in two open-market transactions at weighted average prices of approximately $32.21 and $33.09 per share, for total proceeds of roughly $325,000. According to the Form 4, these sales were automatically executed solely to cover tax withholding obligations arising from the vesting of performance stock units and were not discretionary trades by the insider. Following these withholding-related sales, Bedrosian’s direct ownership stood at 278,064 shares of common stock, implying a remaining equity stake valued at roughly $8.9 million based on the transaction pricing.

Filing Facts

CIK

1658551

Ticker

AMLX

Form

4

Source Type

fda

Accession

0001193125-26-390510

Alert Tier

5